Last reviewed · How we verify
ORKA-001 Induction Dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
ORKA-001 Induction Dose (ORKA-001 Induction Dose) — Oruka Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ORKA-001 Induction Dose TARGET | ORKA-001 Induction Dose | Oruka Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ORKA-001 Induction Dose CI watch — RSS
- ORKA-001 Induction Dose CI watch — Atom
- ORKA-001 Induction Dose CI watch — JSON
- ORKA-001 Induction Dose alone — RSS
Cite this brief
Drug Landscape (2026). ORKA-001 Induction Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/orka-001-induction-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing